BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15583446)

  • 1. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
    Nowak G
    Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):173-83. PubMed ID: 15583446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS; Khan AI; Greilich PE; Kroll MH
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
    Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
    Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
    J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration.
    Casserly IP; Kereiakes DJ; Gray WA; Gibson PH; Lauer MA; Reginelli JP; Moliterno DJ
    Thromb Res; 2004; 113(2):115-21. PubMed ID: 15115666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecarin-Based Methods for Measuring Thrombin Inhibitors.
    Gosselin RC
    Methods Mol Biol; 2023; 2663():355-367. PubMed ID: 37204723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical monitoring of hirudin and direct thrombin inhibitors.
    Nowak G
    Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
    Demir M; Iqbal O; Untch B; Hoppensteadt DA; Gaikwad BS; Fareed J
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):38-43. PubMed ID: 11190903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hirudin determination in plasma can be strongly influenced by the prothrombin level.
    Lindhoff-Last E; Piechottka GP; Rabe F; Bauersachs R
    Thromb Res; 2000 Oct; 100(1):55-60. PubMed ID: 11053617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three methods for measuring PEG-hirudin in blood.
    Hoffmann JJ; Janssen WC
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):577-81. PubMed ID: 11685047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin.
    Lange U; Nowak G; Bucha E
    Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):184-91. PubMed ID: 15583447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative determination of hirudin in blood and body fluids.
    Nowak G; Bucha E
    Semin Thromb Hemost; 1996; 22(2):197-202. PubMed ID: 8807717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of anticoagulant effects of direct thrombin inhibitors.
    Fenyvesi T; Jörg I; Harenberg J
    Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ecarin chromogenic assay: an innovative test for quantitative determination of direct thrombin inhibitors in plasma].
    Lange U; Olschewski A; Nowak G; Bucha E
    Hamostaseologie; 2005 Aug; 25(3):293-300. PubMed ID: 16113754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors.
    Alouidor B; Sweeney RE; Tat T; Wong RK; Yoon JY
    J Extra Corpor Technol; 2019 Mar; 51(1):29-37. PubMed ID: 30936586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional clotting assay to monitor the hirudin dosage.
    Zakir RM; Hoffman W; Bhatt BA; Spillert CR
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
    Callas DD; Fareed J
    Thromb Res; 1996 Sep; 83(6):463-8. PubMed ID: 8885140
    [No Abstract]   [Full Text] [Related]  

  • 20. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G; Roser M; Nauck M
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.